15th Dec 2015 08:40
LONDON (Alliance News) - Cancer drug discovery firm Sareum Holdings PLC was boosted on Tuesday morning after it received formal confirmation that applications for the phase 1 clinical trials on the CCT245737 product will be submitted in January.
The company said the CRT Pioneer Fund, its co-development partner, has confirmed the applications will be submitted to the UK Medicines and Healthcare products Regulatory Agency in January.
"We are delighted to report this significant step towards these two planned clinical trials with cancer patients, and look forward to reporting further progress in due course," said Chief Executive Tim Mitchell.
Sareum shares were up 12% on the news to 0.2075 pence, one of the best performers in the AIM All-Share.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum